B of A Securities Maintains Buy on Xenon Pharmaceuticals, Raises Price Target to $56
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Jason Gerberry has maintained a Buy rating on Xenon Pharmaceuticals (NASDAQ:XENE) and increased the price target from $52 to $56.
January 02, 2024 | 3:48 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
B of A Securities analyst Jason Gerberry maintains a Buy rating on Xenon Pharmaceuticals and raises the price target from $52 to $56.
The increase in price target by B of A Securities reflects a positive outlook on Xenon Pharmaceuticals, which could lead to increased investor confidence and a potential short-term rise in the stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100